** Shares of drugmaker ANI Pharmaceuticals ANI.P rise 2% to $83.51 premarket

** Co says its implant met both main goals in a late-stage study in chronic non-infectious uveitis, a recurring inflammatory eye disease that can cause vision loss

** Trial showed patients gained an average of 3.6 letters in visual acuity, a measure of eyesight, after six months of treatment with Iluvien

** ANI says it also significantly reduced retinal swelling, meeting the study's other main goal

** Iluvien releases a low dose of steroid inside the eye for up to three years

** Most common treatment-related side effects were increased eye pressure (6%) and cataracts (5%), with 29% of patients reporting treatment-related side effects

** Co plans to present detailed study results at medical meetings later this year

** As of last close, stock up 4% YTD